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Abstract
Background: Celastrol is an active ingredient of the traditional Chinese medicinal plant Tripterygium Wilfordii,
which exhibits significant antitumor activity in different cancer models in vitro and in vivo; however, the lack of
information on the target and mechanism of action of this compound have impeded its clinical application. In this
study, we sought to determine the mode of action of celastrol by focusing on the processes that mediate its
anticancer activity.
Methods: The downregulation of heat shock protein 90 (HSP90) client proteins, phosphorylation of c-Jun
NH2-terminal kinase (JNK), and cleavage of PARP, caspase 9 and caspase 3 were detected by western blotting.
The accumulation of reactive oxygen species (ROS) was analyzed by flow cytometry and fluorescence
microscopy. Cell cycle progression, mitochondrial membrane potential (MMP) and apoptosis were determined
by flow cytometry. Absorption spectroscopy was used to determine the activity of mitochondrial respiratory
chain (MRC) complexes.
Results: Celastrol induced ROS accumulation, G2-M phase blockage, apoptosis and necrosis in H1299 and HepG2
cells in a dose-dependent manner. N-acetylcysteine (NAC), an antioxidative agent, inhibited celastrol-induced ROS
accumulation and cytotoxicity. JNK phosphorylation induced by celastrol was suppressed by NAC and JNK inhibitor
SP600125 (SP). Moreover, SP significantly inhibited celastrol-induced loss of MMP, cleavage of PARP, caspase 9 and
caspase 3, mitochondrial translocation of Bad, cytoplasmic release of cytochrome c, and cell death. However, SP
did not inhibit celastrol-induced ROS accumulation. Celastrol downregulated HSP90 client proteins but did not
disrupt the interaction between HSP90 and cdc37. NAC completely inhibited celastrol-induced decrease of HSP90
client proteins, catalase and thioredoxin. The activity of MRC complex I was completely inhibited in H1299 cells
treated with 6 μM celastrol in the absence and presence of NAC. Moreover, the inhibition of MRC complex I
activity preceded ROS accumulation in H1299 cells after celastrol treatment.
Conclusion: We identified ROS as the key intermediate for celastrol-induced cytotoxicity. JNK was activated by
celastrol-induced ROS accumulation and then initiated mitochondrial-mediated apoptosis. Celastrol induced the
downregulation of HSP90 client proteins through ROS accumulation and facilitated ROS accumulation by inhibiting
MRC complex I activity. These results identify a novel target for celastrol-induced anticancer activity and define its
mode of action.
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Celastrol, a quinone methide triterpene, is an active com-
ponent of Tripterygium Wilfordii. Celastrol has been
used in the treatment of autoimmune and neurodegen-
erative diseases for its antioxidative and anti-inflamma-
tory effects [1-4]. Recently, celastrol was found to exhibit
significant anticancer activities in vitro and in vivo,
including the induction of apoptosis in different cancer
cells [5-9], synergistically enhancing the cytotoxicity of
other chemotherapeutic agents [10-12], and inhibiting
the growth of glioma, melanoma and prostate cancer in
nude mice [6,13,14]. However, the target and mechanism
of action of celastrol are not completely clear.
Celastrol has been identified as a novel inhibitor of heat
shock protein 90 (HSP90) and displays anticancer activity
by inducing the degradation of HSP90 client proteins
[7,9,15-17]. In addition, celastrol has been reported to be
a potent inhibitor of proteasomes and induce cytotoxicity
in glioma and prostate cancer models in vivo and in vitro
[8,13]. Several other molecular targets have been pro-
posed to explain the anticancer effects of celastrol,
including NFB [10,18,19], topoisomerase II [5], and xc-
Cystine/Glutamate antiporter [20]. Although these tar-
gets positively correlate with celastrol-induced cytotoxi-
city, it is not clear which, if any, is the principal mediator
of the antitumor activity of celastrol. As celastrol is
moved into clinical studies, it is important to gain a bet-
ter understanding of its target and mechanism.
Reactive oxygen species (ROS) are formed mainly by the
interaction of oxygen molecules with electrons that escape
from the mitochondrial respiratory chain (MRC) [21,22].
ROS are scavenged by antioxidative proteins, including
catalase, superoxide dismutase (SOD) and thioredoxin
(Trx) [23,24]. Inhibiting the activity of MRC complexes
increases the leakage of electrons by blocking the electron
transfer chain, thus promoting ROS production [22,25].
The downregulation of antioxidative proteins decreases
ROS clearance and facilitates ROS accumulation [26].
ROS have been reported to regulate signal transduction
and gene expression and to induce oxidative damage of
nucleic acids, proteins, and lipids [27-29]. Therefore, ROS
play an important role in the processes that determine cell
fate such as proliferation, differentiation and apoptosis
[30-32]. Although low levels of ROS have been reported to
promote cell survival and proliferation, the accumulation
of ROS induces mitochondrial-mediated apoptosis by
facilitating the release of cytochrome c (Cyt c) and apopto-
sis-inducing factor [30,32,33].
In this study, we demonstrate that celastrol-induced
cytotoxicity, including cell growth inhibition, cell cycle
arrest and apoptotic and necrotic cell death, was
mediated by ROS. Moreover, the downregulation of
HSP90 client proteins induced by celastrol was also
ROS-dependent. The accumulation of ROS leds to acti-
vation of c-Jun NH2 terminal kinase (JNK), initiation of
the mitochondrial apoptotic pathway and induction of
cell death. The mechanism by which celastrol induces
ROS accumulation involves the inhibition of MRC com-
plex I activity, but not the expression of antioxidative
proteins. These results present a new target and
mechanism for celastrol-induced cytotoxicity.
Methods
Cells and reagents
H1299 and HepG2 cells were obtained from the Ameri-
can Tissue Culture Collection (Manassas, VA). Cells
were cultured with Dulbecco’s modified Eagle medium
(Gibco, Grand Island, NY) containing 10% fetal bovine
serum (FBS, HyClone, Logan, UT). Celastrol was pur-
chased from Calbiochem (San Diego, CA) and dissolved
in DMSO. N-acetylcysteine and 17-allylamino-17-
demethoxygeldanamycin were purchased from Sigma
( S tL o u i s ,M O ) .S P 6 0 0 1 2 5w a sp u r c h a s e df r o mL C
laboratories (Worburn, MA). Z-VAD-FMK was pur-
chased from R&D Systems (Minneapolis, MN, USA).
Cell viability assay
Cells were collected by trypsinization and incubated
with 0.4% trypan blue for 3 minutes at room tempera-
ture. The viable (unstained) cells were counted and used
to calculate viability.
Cell cycle analysis
50,000 cells were fixed with 70% ethanol containing 1%
FBS at -20°C overnight, and then incubated with RNase
A( 2 0μg/mL) at 37°C for 30 minutes, stained with pro-
pidium iodide (100 μg/mL) for 10 minutes, and then
analyzed by flow cytometry (FACSCalibur, BD, USA)
and ModFit LT software (FACSCalibur, BD, USA). For
each measurement, 20,000 cells were analyzed and the
representative measurements were shown.
Apoptosis and necrosis analysis
Apoptosis and necrosis were determined by a Annexin
V-FITC Kit (Roche, Indianapolis, IN). H1299 and
HepG2 cells were collected by trypsinization. After
washed with PBS, cells were stained with annexin
V-FITC and propidium iodide, and then the apoptosis
and necrosis were determined by flow cytometry (FACS-
Calibur) and CELLQuest software (FACSCalibur). For
each measurement, 20,000 cells were analyzed and the
representative measurements were shown.
Measurement of mitochondrial membrane potential
The mitochondrial membrane potential was measured
with a Mitochondrial Membrane Potential Assay Kit
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according to the manufacturer’s instruction. Briefly,
50,000 cells were collected by trypsinization and incu-
bated with JC-1 for 20 minutes at 37°C in the dark. The
stained cells were washed with ice-cold working solution
twice and then analyzed by flow cytometry (FACSCali-
bur) and CELLQuest software (FACSCalibur). 20,000
cells were analyzed in each measurement. JC-1 aggre-
gates in the polarized mitochondrial matrix and forms
J-aggregates, which emit red fluorescence at 595 nm
when excited at 525 nm. However, JC-1 cannot aggre-
gate in the depolarized mitochondrial matrix and exists
as JC-1 monomers, which emit green fluorescence at
525 nm when excited at 485 nm. Mitochondrial depo-
larization is indicated by a decrease in the red/green
fluorescence intensity ratio.
ROS measurement
ROS were measured by a Reactive Oxygen Species Assay
Kit (Applygen Technologies, Beijing, China). Briefly,
cells were incubated with 3 μMD C F H - D Af o r4 0m i n -
utes at 37°C in the dark, and ROS were determined by
fluorescence microscopy or flow cytometry (FACSCali-
bur) at an excitation wavelength of 480 nm and an
emission wavelength of 525 nm. More than 3 fields
were observed by fluorescence microscope and 20,000
stained cells were analyzed with flow cytometry in each
measurement. The ROS fold was calculated based on
the mean geometry fluorescence determined by flow
cytometry and shown as a histogram.
Immunoprecipitation and western blot analysis
Immunoprecipitation and western blotting were per-
formed according to the method described by Yu [34].
For immunoprecipitation experiments, cells were lysed
in TNESV buffer containing 50 mM Tris (pH 7.5),
2 mM EDTA, 100 mM NaCl, 2% Nonidet P-40 (NP-40),
1 mM Na3VO4 and cocktail (1 tablet/10 mL solution,
Roche, Indianapolis, USA) at 4°C for 30 minutes. Cell
lysates were centrifuged at 10,000 g to remove cellular
debris. Protein concentration in the lysate was quanti-
fied with a Bicinchoninic Acid (BCA) Protein Assay Kit
(Pierce, Rockford, IL, USA). Approximately 500 μg total
proteins was incubated with 2 μg heat shock protein 90
antibody (Stressgen, Victoria, British Columbia, Canada)
at 4°C for 12 h, after which 20 μL of protein A/G Plus
Agarose (Santa Cruz, CA, USA) was added into the mix-
ture and incubated for 2 h at 4°C. Agarose-antibody-
protein complexes were washed one time with lysis buf-
fer and two times with PBS. The immune complexes
were resuspended in 20 μL of Laemmli Buffer (Bio-Rad
Laboratories, CA, USA) and boiled for 5 minutes. The
samples were analyzed by western blotting.
For western blotting experiments, cells were lysed in
Laemmli Buffer (Bio-Rad Laboratories) and protein con-
centration in the lysate was quantified by a BCA Protein
Assay Kit (Pierce,). Fifty micrograms of total protein was
subjected to SDS-PAGE and transferred onto a PVDF
membrane. The membrane was blotted with primary
antibodies for 12-15 h at 4°C and incubated with horse-
radish peroxidase-conjugated secondary antibody for 1 h
at room temperature. Proteins were detected using a
SuperEnhanced Chemiluminescence Detection Kit
(Applygen Technologies). The antibodies used in the
study were anti-PARP, cleaved caspase 3, caspase 9,
phospho-JNK, JNK, AKT, epidermal growth factor
receptor, heat shock protein 90, CDK4 and Thioredoxin
(Cell Signaling, Beverly, MA); anti-catalase (Abcam,
Cambridge, MA); anti-Bad (Transduction Laboratories,
KY); anti-cytochrome c, superoxide dismutase and
Cdc37 (Santa Cruz,) and anti-b-actin (Oncogene,
Boston).
Mitochondria isolation
T h em i t o c h o n d r i aw e r ei s o l a t e dw i t haM i t o c h o n d r i a l
Isolation Kit (Applygen Technologies). Fifty million cells
were resuspended with ice-cold Mito-Cyto isolation buf-
fer and homogenized with the grinder. Homogenate was
centrifuged at 800 g for 10 minutes at 4°C. The super-
natants were collected in a new tube, and centrifuged at
10,000 g for 10 minutes at 4°C. The supernatant and
pellet were saved as cytosolic fraction and intact mito-
chondria, respectively. The intact mitochondria were
lysed with Laemmli Buffer (Bio-Rad Laboratories) to
extract mitochondrial protein. The alteration of Bad and
cytochrome c in mitochondria and cytoplasm were ana-
lyzed by western blotting.
Measurement of MRC Complexes Activity
The activity of MRC complexes was determined with
Mitochondrial Respiratory Chain Complexes Activity
Assay Kits (Genmed Scientifics, Shanghai, China).
B r i e f l y ,t h ei s o l a t e dm i t o c h o n d r i aw e r er e s u s p e n d e d
with the Mito-Cito buffer (Applygen Technologies), fro-
z e na t- 7 0 ° Ca n dt h a w e da t3 7 ° Ct h r e et i m e st oe x t r a c t
the mitochondrial proteins. The protein concentration
in the lysate was determined using the BCA Protein
Assay Kit (Pierce, Rockford) and diluted to 0.1 μg/μL.
The absorbance was determined on a Smartspec™ Plus
spectrophotometer (Bio-Rad). The activity of complex I-
linked NADH-ubiquinone reductase was determined by
measuring the reduction of ubiquinone to ubiquinol,
which leads to a decrease in absorbance of NADH at
340 nm. The activity was measured with or without
rotenone, a specific inhibitor of NADH-ubiquinone
reductase. The specific activity of complex I was
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activity from the total activity and is expressed as μM
NADH mg/min. Complex II-linked succinate-ubiqui-
none reductase activity was determined by measuring
the reduction of 2,6-dichlorophenolindophenol (DCIP),
which can be monitored at 600 nm. The activity is
expressed as μM DCIP mg/min. Complex III-linked ubi-
quinol cytochrome c reductase activity was determined
by monitoring the reduction of cytochrome c by the
electrons donated from ubiquinol, which can be moni-
tored at 550 nm. The activity was measured with or
without antimycin A, a specific inhibitor of ubiquinol
cytochrome c reductase. The specific activity of complex
III was calculated by subtracting the antimycin A-non-
sensitive activity from the total activity and is expressed
as μM CoQH2 mg/min. Complex IV-linked cytochrome
c oxidoreductase activity was determined by measuring
the oxidation of cytochrome c, which can be monitored
at 550 nm. The activity was expressed as μMC y tc
mg/min. All measurements were performed in triplicate.
Statistical Analysis
Statistical significance was analyzed by ANOVA test or
unpaired t test. Statistical significance was defined as
p < 0.01. All experiments were repeated at least three
times, and data are expressed as the mean ± SD (stan-
dard deviation) from a representative experiment.
Results
Celastrol initiates ROS accumulation and mediates
cytotoxicity in a dose-dependent manner
To determine the role of ROS in mediating celastrol-
induced cytotoxicity, we first measured ROS levels in
H1299 and HepG2 cells after celastrol exposure. As
shown in Figure 1A, celastrol increased ROS levels in a
dose-dependent manner in both H1299 and HepG2
cells. Celastrol also reduced cell viability in both H1299
and HepG2 cells in a dose-dependent manner (Figure
1B). Celastrol arrested cell cycle in both cell lines, and
the G2-M phase ratio rose from 15 ± 1.6% to 41 ± 3.1%
in H1299 cells and 15 ± 1.8% to 34 ± 3.5% in HepG2
cells after 24 h of treatment with 6 μMc e l a s t r o l
(Figure 1C). The results of annexin V-FITC and propi-
dium iodide (PI) staining showed that celastrol induced
apoptotic and necrotic cell death in a dose-dependent
manner, and the percent of cell death (apoptosis and
necrosis) was 41 ± 4.1% in H1299 cells and 22 ± 2.5%
in HepG2 cells treated with 6 μM celastrol for 24 h
( F i g u r e1 D ) .T h e r e f o r e ,R O Sl e vels positively correlate
with cell death and growth arrest induced by celastrol.
Moreover, scavenging of ROS by the antioxidative
agent N-acetylcysteine (NAC) inhibited celastrol-
induced decrease in cell viability, cell cycle arrest and
cell death (Figure 1). As ROS have been reported to
mediate the cytotoxicity induced by some cytotoxic
agents [22,25], we assumed that ROS played a critical
role in mediating celastrol-induced cytotoxicity as well.
Celastrol-induced decrease of HSP90 client proteins is
mediated by ROS
Celastrol has been identified as a novel HSP90 inhibitor
and mediates cytotoxicity by facilitating the degradation
of HSP90 client proteins [7,9,15-17]. Thus, we deter-
mined whether ROS were involved in mediating the
decline of HSP90 client proteins induced by celastrol.
Levels of the HSP90 client proteins including AKT, epi-
dermal growth factor receptor (EGFR) and CDK4 were
all decreased following celastrol treatment in H1299
cells (Figure 2A). However, the decrease of HSP90 client
proteins induced by celastrol was completely inhibited
by NAC (Figure 2A). To determine whether the decline
of HSP90 client proteins induced by celastrol was
dependent on apoptosis, we analyzed the effect of celas-
trol on HSP90 client protein expression in the absence
and presence of Z-VAD-FMK (Z-VAD), a pan-caspase
inhibitor. As shown in Figure 2B, 50 μM Z-VAD signifi-
cantly decreased the cleavage of PARP (apoptosis mar-
ker) induced by celastrol, indicating that Z-VAD
inhibited celastrol-induced apoptosis. However, Z-VAD
had no significant effect on celastrol-induced decrease
of HSP90 client proteins including EGFR, AKT and
CDK4, suggesting that celastrol-induced decrease of
HSP90 client proteins is not dependent on apoptosis. By
using a GST pull-down assay, a previous study has
reported that celastrol could disrupt the HSP90/Cdc37
complex [15]; however, we did not observe that the
interaction between endogenous HSP90 and Cdc37 was
disrupted by celastrol in H1299 cells (Figure 2C). In
addition, we compared the effect of NAC in reversing
the decrease of HSP90 client proteins induced by 17-
allylamino-17-demethoxygeldanamycin (17-AAG), a
classic HSP90 inhibitor, with that induced by celastrol.
Both 17-AAG and celastrol induced the depletion of
HSP90 client proteins including AKT and EGFR
whereas NAC blocked celastrol-induced depletion of
ATK and EGFR but had no effect on 17-AAG-induced
HSP90 client protein degradation (Figure 2D). These
data indicate that celastrol-induced inhibition of HSP90
chaperone function is mediated by ROS.
Celastrol induces ROS accumulation by inhibiting the
activity of MRC complex I
ROS play a critical role in mediating the cytotoxicity
induced by celastrol, but the targets by which celastrol
induces ROS accumulation are unknown. To identify the
targets for celastrol-induced ROS accumulation, we first
measured ROS levels in H1299 cells at different time
points after celastrol exposure. As shown in Figure 3A,
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Page 4 of 13Figure 1 ROS mediate cell death and growth arrest induced by celastrol. H1299 and HepG2 cells were treated with the indicated
concentration of celastrol (Cel) in the absence or presence of 5 mM NAC for 24 h. A. Celastrol induces dose-dependent ROS accumulation. Cells
were stained with DCFH-DA and washed with PBS. More than three fields in each group were observed by fluorescence microscope (200×), and
representative images are shown. B. ROS mediate the reduction of cell viability induced by celastrol. Viable cells were counted by trypan blue
exclusion. Representative measurements of at least three independent experiments are shown. The values reported represent the mean ± SD of
three separate experiments. *P < 0.01. C. ROS mediate G2-M phase blockage induced by celastrol. Cells were stained with PI and analyzed by
flow cytometry. Representative measurements of at least three independent experiments are shown. The values reported represent the mean ±
SD of three separate experiments. *P < 0.01 compared with control cells. D. ROS mediate apoptosis and necrosis induced by celastrol. Cells were
stained with PI and annexin V-FITC and analyzed by flow cytometry. Representative measurements of at least three independent experiments are
shown. The values of cell death (apoptosis and necrosis) reported represent the mean ± SD of three separate experiments. *P < 0.01 compared
with control cells.
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H1299 cells, and ROS levels increased 7.7 ± 0.7 times
after 1 h of celastrol treatment. The downregulation of
antioxidative proteins results in ROS accumulation [24];
therefore, we investigated the effect of celastrol on the
expression of antioxidative proteins, including catalase,
SOD, and Trx. Celastrol had no significant effect on SOD
but slightly downregulated catalase and Trx expression (Fig-
ure 3B). However, the downregulation of catalase and Trx
was completely inhibited by NAC (Figure 3B). Therefore,
celastrol does not cause ROS accumulation by downregulat-
ing the antioxidative proteins SOD, catalase, and Trx.
Inhibiting the activity of MRC complexes promotes
ROS production [25]. Therefore, we speculated that
celastrol may induce ROS accumulation by inhibiting
MRC complex activity. We detected the effect of celas-
trol on different MRC complexes. Celastrol completely
inhibited MRC complex I activity but increased MRC
complex IV activity (Figure 3C), indicating that complex
I, but not complex IV, may be the target of celastrol in
mediating ROS accumulation. The activity of MRC
complex II and III decreased in H1299 cells treated
with celastrol; however, NAC reversed the inhibition
(Figure 3C), indicating that complex II and III are not
likely targets of celastrol for ROS accumulation. In addi-
tion, MRC complex I activity was completely inhibited
as early as 30 minutes after celastrol exposure (Figure
3D), which precedes ROS accumulation. In contrast, the
activity of MRC complex II, III and IV did not signifi-
cantly decrease after 30 or 60 minutes of treatment with
celastrol (Figure 3D), further confirming that complex I
is the target of celastrol in promoting ROS production.
Celastrol-induced activation of the mitochondrial
apoptotic pathway is mediated by ROS
Because celastrol induced apoptosis in a dose-dependent
manner (Figure 1D), we further investigated the effect of
celastrol on mitochondria. The mitochondrial mem-
brane potential (MMP) was measured using a JC-1
fluorescent probe, and the JC-1 red/green fluorescence
intensity ratio was used to represent MMP. As shown in
Figure 4A, celastrol treatment resulted in a dose-
Figure 2 ROS mediate the decrease of HSP90 client proteins induced by celastrol. A. ROS mediate the decrease of HSP90 client proteins
induced by celastrol. H1299 and HepG2 cells were treated with the indicated concentrations of celastrol in the absence or presence of 5 mM
NAC for 24 h. The alteration of PARP, EGFR, AKT, CDK4 and actin was analyzed by western blotting. B. Celastrol-induced decrease of HSP90 client
proteins is independent of apoptosis. H1299 cells were treated with or without 4 μM celastrol in the absence or presence of 50 μM Z-VAD for
24 h. The alteration of PARP, EGFR, Akt, CDK4 and actin was analyzed by western blotting. C. Celastrol does not disrupt the interaction between
HSP90 and Cdc37 in H1299 cells. H1299 cells were treated with or without 6 μM celastrol for 12 h in the absence and presence of 5 mM NAC.
Cell lysate was immunoprecipitated with an HSP90 antibody. Western blotting was used to detect HSP90 and Cdc37. D. NAC does not inhibit
the degradation of EGFR and AKT induced by 17-AAG. H1299 cells were treated with or without 5 μM 17-AAG and 6 μM celastrol for 24 h in the
absence and presence of 5 mM NAC. The alteration of EGFR, AKT and actin was analyzed by western blotting. All of the above experiments
were repeated multiple times, and similar results were obtained each time; therefore, representative images are shown.
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Page 6 of 13Figure 3 Inhibition of MRC complex I activity is involved in mediating ROS accumulation induced by celastrol. A. Celastrol induces time-
dependent ROS accumulation. H1299 cells were treated with 6 μM celastrol for the designated time. Cells were stained with DCFH-DA and
analyzed by flow cytometry. The relative levels of ROS geometry fluorescence are shown as a ratio compared to the control group.
Representative measurements of at least three independent experiments are shown. The values reported represent the mean ± SD of three
separate experiments. *P < 0.01 compared with control cells. B. The alteration of antioxidative proteins induced by celastrol is not involved in
promoting ROS accumulation. H1299 cells were treated with the indicated concentration of celastrol in the absence or presence of 5 mM NAC
for 24 h. The alteration of SOD, catalase, Trx and actin was analyzed by western blotting. Representative images of at least three independent
experiments are shown. C. Celastrol significantly inhibits MRC complex I activity. H1299 cells were treated with or without 6 μM celastrol in the
absence or presence of 5 mM NAC for 12 h. The activity of MRC complexes was measured with a Mitochondrial Respiratory Chain Complex
Enzyme Activity Assay Kit and is displayed as a histogram. All columns display the mean ± SD from three independent experiments. *P < 0.01.
D. Inhibition of MRC complex I activity is involved in mediating ROS accumulation induced by celastrol. H1299 cells were treated with 6 μM
celastrol for the indicated time. The activities of MRC complexes were measured by Mitochondrial Respiratory Chain Complex Enzyme Activity
Assay Kits and are displayed as a histogram. All columns display the mean ± SD from three independent experiments. *P < 0.01 compared with
control cells.
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Page 7 of 13Figure 4 Celastrol induces apoptosis through ROS accumulation and subsequent JNK activation. A. ROS mediate the depolarization of
mitochondria induced by celastrol. H1299 cells were treated with the indicated concentration of celastrol in the absence or presence of 5 mM
NAC for 24 h. Cells were stained with JC-1 and analyzed by flow cytometry. The ratio of JC-1 red/green fluorescence intensity was normalized by
comparing it to the control group and is represented as loss of MMP. Representative measurements of at least three independent experiments
are shown. The values reported represent the mean ± SD of three separate experiments. *P < 0.01 compared with the control group. B. Celastrol
induces caspase-dependent apoptosis. H1299 cells were treated with the indicated concentration of celastrol in the absence or presence of 5
mM NAC for 24 h. Actin and the cleavage of PARP, caspase 9 and caspase 3 were analyzed by western blotting. Representative images of at
least three independent experiments are shown. C. ROS mediate JNK activation induced by celastrol. H1299 cells were treated with the indicated
concentration of celastrol in the absence or presence of 5 mM NAC for 12 h. The alteration of phospho-JNK (p-JNK), total JNK (t-JNK) and actin
were analyzed by western blotting. Representative images of at least three independent experiments are shown. D. JNK mediates celastrol-
induced cell death. H1299 cells were treated with the indicated concentration of celastrol in the absence or presence of 40 μM SP for 24 h. Cells
were stained with PI and annexin V-FITC and analyzed by flow cytometry. Representative measurements of at least three independent
experiments are shown. The values reported represent the mean ± SD. *P < 0.01.
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red/green fluorescence intensity ratio in H1299 cells
treated with 6 μM celastrol for 24 h decreased to 2 ±
0.2%, indicating that celastrol significantly induced dys-
function of mitochondria. As before, NAC inhibited the
decrease of MMP induced by celastrol (Figure 4A), indi-
cating that ROS were involved in mediating mitochon-
drial depolarization. Moreover, as shown in Figure 4B,
NAC could completely block the cleavage of PARP,
caspase 9, and caspase 3 in H1299 cells treated with
celastrol. These data are consistent with celastrol
induced mitochondrial-mediated apoptosis through ROS
accumulation.
Celastrol activates JNK through ROS accumulation, which
plays a critical role in mediating the activation of
mitochondrial apoptotic pathway
As the stress-activated protein kinase, JNK can be acti-
vated by oxidative stress induced by accumulated ROS
[35,36]. Activated JNK initiates the mitochondrial apop-
totic pathway by mediating the activation and mitochon-
drial translocation of proapoptotic proteins including
Bax and Bad [37-39]. We determined the effect of celas-
trol on JNK activation. As shown in Figure 4C, celastrol
increased the level of JNK phosphorylation in a dose-
dependent manner whereas NAC completely inhibited
celastrol-induced JNK phosphorylation, demonstrating
that JNK was activated by celastrol-induced ROS
accumulation. The results of annexin V-FITC and PI
staining showed that JNK inhibitor SP600125 (SP)
significantly inhibited celastrol-induced apoptosis and
necrosis. The percentage of cell death (apoptosis and
necrosis) was 43 ± 4.1% in cells treated with celastrol and
11 ± 1.2% in cells treated with celastrol and SP (Figure 4D).
We further determined the mechanism by which JNK
mediates celastrol-induced cell death. As shown in
Figure 5A, SP did not suppress celastrol-induced ROS
accumulation, indicating that SP does not inhibit celas-
trol-induced cell death by suppressing ROS accumula-
tion. However, SP significantly inhibited celastrol-
induced depolarization of mitochondria. The JC-1 red/
green fluorescence intensity ratio was 7 ± 1.4% and
68 ± 4.2% in H1299 cells treated with 6 μMc e l a s t r o l
alone and 6 μM celastrol with SP for 24 h, respectively
(Figure 5B). Moreover, SP inhibited celastrol-induced
JNK phosphorylation and cleavage of PARP, caspase 9
and caspase 3 (Figure 5C). Furthermore, SP signifi-
cantly inhibited mitochondrial translocation of Bad
and cytoplasmic release of Cytochrome c induced by
celastrol (Figure 5D). Therefore, ROS-induced JNK
activation played a crucial role in initiating mitochon-
dria-mediated apoptosis of H1299 cells treated with
celastrol.
Discussion
Celastrol displays significant anti-cancer activity in vivo
and in vitro in various cancer models [5,7,13,18], but
the precise target and mechanism are not clear. In this
study, we demonstrate that celastrol induces cytotoxicity
by causing ROS accumulation. Accumulated ROS inhib-
ited HSP90 function, activated JNK, and induced cell
cycle arrest and apoptotic and necrotic cell death. The
effects of celastrol on ROS accumulation and apoptosis
were observed in both lung cancer cells (H1299) and
hepatoma cells (HepG2). Therefore, we conclude that
ROS represent a novel intermediate in mediating celas-
trol-induced cytotoxicity.
As the stress-activated protein kinase, JNK plays a cri-
tical role in mediating apoptotic cell death [36]. It has
been previously reported that celastrol activates JNK by
suppressing the transcriptional activity of ATF2 [6].
However, we observed that JNK was activated by celas-
trol-induced ROS accumulation. Recent studies have
indicated that ROS play important roles in regulating
both normal cellular processes, such as proliferation, dif-
ferentiation and migration, and disease progression, such
as cancer [30-33]. Accumulated ROS have been identi-
fied as the key intermediate for the cytotoxicity induced
by many chemotherapeutic agents [22,38,40]. In cells,
many antioxidative enzymes respond to scavenge ROS
and maintain low levels of cellular ROS. Among the
antioxidative system, catalase, SOD and Trx are the
main proteins involved in ROS clearance, and some che-
motherapeutic agents induce ROS-dependent cytotoxi-
city by downregulating the expression of these
antioxidative proteins [23,24,41,42]. However, in our
study, we found that celastrol did not affect the expres-
sion of SOD and only slightly downregulated catalase
and Trx expression at a high dose, which was inhibited
by NAC. Therefore, we concluded that celastrol did not
induce ROS-dependent cytotoxicity by inducing dys-
function of the antioxidative system. Though many
enzymes, including NADPH oxidase, cytochrome c oxi-
dase and lipoxygenase, respond to ROS production, the
main source of ROS generation is the MRC [21]. Some
cytotoxic agents, such as rotenone, have been shown to
induce ROS-dependent cytotoxicity by targeting MRC
complex I [22,25]. In this study, we found that after
exposure of 6 μM celastrol for 30 minutes, the cellular
activity of MRC complex I was completely inhibited
(Figure 3C). This inhibitory effect was not reversed by
NAC, demonstrating that inhibition of MRC complex I
activity contributes to celastrol-induced ROS accumula-
tion. However, whether celastrol can directly inhibit
MRC complex I activity requires further study.
Previous studies have reported that celastrol inhibits
lipid peroxidation in rat liver mitochondrial membranes
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Page 9 of 13Figure 5 JNK mediates celastrol-induced cell death by initiating the mitochondrial apoptotic pathway. H1299 cells were treated with the
indicated concentration of celastrol in the absence or presence of 40 μM SP for 12 h or 24 h. A. SP does not suppress celastrol-induced ROS
accumulation. After 12 h of treatment, cells were stained with DCFH-DA and analyzed by flow cytometry. The relative levels of ROS geometry
fluorescence are shown as a ratio compared to the control group. Representative measurements are shown. Each experiment was performed in
triplicate, and the values reported represent the mean ± SD. B. JNK mediates mitochondrial depolarization induced by celastrol. Cells were
stained with JC-1 and analyzed by flow cytometry. The ratio of JC-1 red/green fluorescence intensity was normalized by comparing the data to
the control group and is represented as loss of MMP. Representative measurements are shown. Each experiment was performed in triplicate, and
the values reported represent the mean ± SD. *P < 0.01. C. JNK mediates celastrol-induced apoptosis by initiating the mitochondrial apoptotic
pathway. Actin, p-JNK, t-JNK and the cleavage of PARP, caspase 9 and caspase 3 were analyzed by western blotting. Representative images of
three independent experiments are shown. D. JNK mediates mitochondrial translocation of Bad and cytoplasmic release of Cyt c induced by
celastrol. Mitochondria and cytoplasm were separated and used to extract protein. The alteration and subcellular localization of Bad and Cyt c
were analyzed by western blotting. Representative images of three independent experiments are shown.
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Page 10 of 13induced by ADP and Fe
2+ [43,44]. These results conflict
with our results that celastrol induces oxidative stress by
causing ROS accumulation in H1299 and HepG2 cells.
It is possible that this discrepancy may be attributed to
the difference between normal tissues (rat liver mito-
chondrial membrane) and cancer cells (non-small lung
cancer cells and hepatoma cells). Celastrol has been
reported to protect neuronal cells from cytotoxicity by
increasing the expression of heat shock proteins and
suppressing the release of inflammatory intermediates
[1,3]. However, celastrol inhibits pro-inflammatory cyto-
kine secretion and promotes expression of heat shock
proteins at nanomolar concentrations whereas the cyto-
toxic concentration of celastrol for neuronal cells is
approximately 1 μM [2,3]. Therefore, it seems that the
protective or cytotoxic role of celastrol is dependent on
the dose.
HSP90 is a highly abundant molecular chaperone
that maintains the stability and activity of multiple
kinases, transcription factors and steroid receptors
[45,46]. The classic HSP90 inhibitors, such as geldana-
mycin (GA) and 17-AAG, inhibit HSP90 chaperone
function by competing with ATP for the ATP-binding
pocket of HSP90 and then facilitate the degradation of
HSP90 client proteins [47]. Celastrol has been identi-
fied as an inhibitor of HSP90 and displays cytotoxicity
by inducing the degradation of HSP90 client proteins
[7,9,16]. Consistent with these previous reports, we
found that celastrol induced the downregulation of
EGFR, AKT and CDK4. However, we found that celas-
trol-induced decrease of HSP90 client proteins was
inhibited by scavenging ROS. Recently, GA and 17-
AAG have been shown to promote superoxide genera-
tion [48,49], but it has been suggested that oxidative
stress alone is insufficient to disrupt HSP90 binding to
its client proteins [48]. Consistent with this result, our
data also show that NAC could not block the degrada-
tion of AKT and EGFR induced by 17-AAG. Com-
pared with 17-AAG, ROS obviously play a key role in
mediating the downregulation of HSP90 client proteins
induced by celastrol.
Although a previous study attributed the mechanism
for celastrol-induced degradation of HSP90 client pro-
teins to the disruption of HSP90/Cdc37 complex [7], we
did not find that the interaction of HSP90 and Cdc37
was disrupted by 6 μM celastrol, either in the absence
or in the presence of NAC. Another report also verified
that 5 μM celastrol had no effect on the interaction of
HSP90 and Cdc37; only 10 μM celastrol showed the
ability to decrease the interaction of HSP90 and Cdc37
[15]. Therefore, celastrol-induced disruption of the
HSP90/Cdc37 complex appears to be highly dose-
dependent. Because the doser e q u i r e dt od i s r u p tt h e
HSP90/Cdc37 complex is higher than the IC50 [7], it is
not clear whether the cytotoxic effect of celastrol is due
to the disruption of the interaction between HSP90 and
Cdc37. In view of our finding that 6 μM celastrol did
not disrupt the interaction between HSP90 and Cdc37,
we conclude that ROS mediate the degradation of
HSP90 client proteins through other pathways. It is pos-
sible that aberrant ROS cause oxidative damage to pro-
teins, which promotes their degradation [50].
Conclusions
In conclusion, we demonstrate that celastrol targets
MRC complex I and induces ROS accumulation and
that accumulated ROS act as the key intermediate that
induces cell cycle arrest, inhibits HSP90 chaperone func-
tion, downregulates HSP90 client proteins, activates JNK
and initiates apoptotic and necrotic cell death (Figure
6). Therefore, the present study identifies a new target
and a new mechanism for the anti-cancer activity dis-
played by celastrol.
Figure 6 Model of ROS-mediated cytotoxicity induced by
celastrol. Celastrol facilitates ROS accumulation in tumor cells by
inhibiting the activity of MRC complex I. ROS then induce apoptosis
and necrosis by activating JNK and downregulating HSP90 client
proteins including EGFR, AKT and CDK4. ROS also mediate cell
growth arrest by inducing G2-M phase blockage in tumor cells after
celastrol treatment.
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